Home/Pipeline/DE-128A

DE-128A

Presbyopia

Phase 2Active

Key Facts

Indication

Presbyopia

Phase

Phase 2

Status

Active

Company

Santen Pharmaceutical

About Santen Pharmaceutical

Santen's mission is to contribute to the well-being of patients, society, and employees by addressing ophthalmic diseases through specialized innovation. The company has achieved a leading global position in ophthalmology with a robust commercial portfolio and a deep R&D pipeline focused on glaucoma, retinal diseases, and ocular surface disorders. Its strategy is built on a vertically integrated, ophthalmology-focused model that enables deep expertise, operational efficiency, and targeted global expansion in both developed and emerging markets.

View full company profile

Therapeutic Areas

Ophthalmology Eye Care

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	NDA Submitted	Active
Presbyopia-Correcting ICL	STAAR Surgical	Research & Development	Active R&D
LB-01	Lento Bio	Discovery/IND-Enabling	Active
LB-02	Lento Bio	Discovery	Active
Presbyopia-Correcting Contact Lenses	Clerio Vision	Development	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
NVK029	Vyluma	Phase 2	Active
ArtiPlus	Ophtec	Clinical Trials	Active
BRIMOCHOL™ PF	Tenpoint Therapeutics	NDA Submitted	Active
Qlosi™	Orasis Pharmaceuticals	Approved	Active
TSH‑001	TSH Biopharm	Phase 1/2	Active
YP-10	Viatris	NDA Filed	Under FDA Review (PDUFA date set)